Huizhe Wu

Publications (2)5.88 Total impact

• Article: Association of XPC polymorphisms with susceptibility and clinical outcome to chemotherapy in breast cancer patients.

  Xiuli Yang, Duo Liu, Huizhe Wu, Hui Kang, Hao Pang, Desheng Huang, Xianzheng Sha, Enhua Wang, Zhe Wang, Minjie Wei
  [show abstract] [hide abstract]
  ABSTRACT: The aim of the current study was to evaluate the relation between the Xeroderma pigmentosum complementation group C (XPC) polymorphisms and the susceptibility of breast cancer (BC), development, progression of diseases and response to different individualized drug treatments. We investigated two polymorphisms in XPC Ala499Val and Lys939Gln using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assays including 618 cases and 622 controls. The frequency of the TT genotype of Ala499Val (adjusted OR=1.575; 95% CI, 1.104-2.245, P=0.012) and the AC genotype of Lys939Gln (adjusted OR=1.330, 95%CI: 1.045-1.694, P =0.020) were found to significantly increase the risk of developing BC. The CT+TT genotypes of Ala499Val were associated with estrogen receptor (ER) positive, human epidermal growth factor receptor (Her-2), and tumor protein 53 (p53) negative status and the AC+CC genotypes of Lys939Gln were associated with breast cancer type 1 susceptibility protein (BRCA1) negative status. Moreover, a significantly increased chance of treatment with neoadjuvant anthracycline-based chemotherapy response was found in women carrying TT genotype of Ala499Val, or CC and AC genotypes of Lys939Gln. In addition, a significantly longer overall survival (OS) after chemotherapy was observed in patients who had XPC Lys939Gln AC+CC genotypes with ER positive (Log-rank test: P=0.086) and p53 negative (Log-rank test: P=0.020). The current data suggested that XPC Ala499Val and Lys939Gln polymorphisms may contribute to the identification of patients with increased risk for BC. Moreover, the polymorphisms were associated with the prognosis of BC patients.
  Cancer Science 04/2012; · 3.33 Impact Factor
• Article: Roles of ABCB1 gene polymorphisms and haplotype in susceptibility to breast carcinoma risk and clinical outcomes.

  Huizhe Wu, Hui Kang, Yong Liu, Weiwei Tong, Duo Liu, Xiuli Yang, Minqiong Lian, Weifan Yao, Haishan Zhao, Desheng Huang, Xianzheng Sha, Enhua Wang, Minjie Wei
  [show abstract] [hide abstract]
  ABSTRACT: Genetic variants of ABCB1 gene contributed to cancer susceptibility and interindividual differences in chemotherapy response. Therefore, we investigated the relevance between genetic variations in ABCB1 gene and both risk and clinical outcomes of breast carcinoma. A case-control study was performed on the SNPs C3435T, C1236T and G2677T/A in 1,173 Chinese breast carcinoma patients and 1,244 age- and sex-matched controls. These SNPs were typed by PCR-restriction fragment length polymorphism assays. We found the following: (1) ABCB1 C3435T, G2677T/A variants and haplotype 3435T-1236T-2677T significantly increased the risk of breast carcinoma [adjusted OR (95 % CI): 1.281 (1.021-1.285), 1.326 (1.182-1.487) and 1.707 (1.498-1.945), respectively]. (2) A significantly enhanced therapeutic response was observed in both C3435T variants and haplotype 3435T-1236T-2677T after neoadjuvant anthracycline-based chemotherapy (n = 148) [adjusted OR (95 % CI): 2.695 (1.172-6.211) and 8.064 (1.085-58.823), respectively]. (3) Cox proportional hazards regression models showed that the hazards ratio (HR) for progression-free survival (PFS) associated with C3435T CC genotype was 1.664 (95 % CI: 1.022-2.708, P = 0.041). Kaplan-Meier curve showed that C3435T CC carriers had a poor prognosis than those with CT/TT carriers after anthracycline-based chemotherapy (P = 0.043, n = 762). Furthermore, ABCB1 C3435T variants showed a significantly prolonged both PFS and overall survival (OS) in patients with triple-negative (ER-/PR-/HER2-) status (P = 0.001 and P = 0.016, respectively; n = 135). In addition, there was a significantly longer OS in patients with HER2-negative status who had G2677T/A variants (P = 0.036, n = 487). However, we did not find statistically significant association between C1236T genotypes and the risk or prognosis of breast carcinoma. These results suggest that ABCB1 gene C3435T, G2677T/A variations and haplotype 3435T-1236T-2677T relate to the risk and clinical outcomes of breast carcinoma and may function as candidate molecular markers of anthracycline chemosensitivity in breast carcinoma.
  Journal of Cancer Research and Clinical Oncology 04/2012; 138(9):1449-62. · 2.56 Impact Factor